473 related articles for article (PubMed ID: 1946795)
1. Hypertension strategies for therapeutic intervention and prevention of end-organ damage.
Houston MC
Prim Care; 1991 Sep; 18(3):713-53. PubMed ID: 1946795
[TBL] [Abstract][Full Text] [Related]
2. [Are all antihypertensive drugs renoprotective?].
Wolf S; Risler T
Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
[TBL] [Abstract][Full Text] [Related]
3. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
[TBL] [Abstract][Full Text] [Related]
4. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hypertension in chronic kidney disease.
Toto RD
Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
[TBL] [Abstract][Full Text] [Related]
6. ESH-ESC guidelines for the management of hypertension.
Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
[TBL] [Abstract][Full Text] [Related]
7. [Retrospective studies and prospects of therapy for hypertension].
Maisch B; Brilla C; Kruse T; Noll B; Bethge C
Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
[TBL] [Abstract][Full Text] [Related]
8. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
Oparil S; Bakir SE
Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
[TBL] [Abstract][Full Text] [Related]
9. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
10. The future of antihypertensive treatment.
Israili ZH; Hernández-Hernández R; Valasco M
Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
[TBL] [Abstract][Full Text] [Related]
11. Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection.
Gosse P
Expert Rev Cardiovasc Ther; 2006 May; 4(3):319-33. PubMed ID: 16716093
[TBL] [Abstract][Full Text] [Related]
12. Clinical overview of antihypertensive classes--clinically relevant differences: myths or facts? Based on a presentation by Alan H. Gradman, MD.
Am J Manag Care; 2000 Mar; 6(4 Suppl):S197-210. PubMed ID: 10977460
[TBL] [Abstract][Full Text] [Related]
13. Study population and treatment titration in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT).
Brown MJ; Castaigne A; de Leeuw PW; Mancia G; Rosenthal T; Ruilope LM
J Hypertens; 1998 Dec; 16(12 Pt 2):2113-6. PubMed ID: 9886905
[TBL] [Abstract][Full Text] [Related]
14. [Drug therapy of arterial hypertension. Reflections and suggestions].
Franchi F; Fabbri G
Clin Ter; 1989 May; 129(4):299-313. PubMed ID: 2527124
[TBL] [Abstract][Full Text] [Related]
15. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
[TBL] [Abstract][Full Text] [Related]
16. Optimizing management of hypertension with combination therapy: considerations for the nurse practitioner.
Roberts ME; Epstein BJ
J Cardiovasc Nurs; 2009; 24(5):380-9. PubMed ID: 19707098
[TBL] [Abstract][Full Text] [Related]
17. The metabolic syndrome in hypertension: European society of hypertension position statement.
Redon J; Cifkova R; Laurent S; Nilsson P; Narkiewicz K; Erdine S; Mancia G;
J Hypertens; 2008 Oct; 26(10):1891-900. PubMed ID: 18806611
[TBL] [Abstract][Full Text] [Related]
18. Choice of antihypertensive drug in the diabetic patient.
Ong HT; Cheah JS
MedGenMed; 2005 May; 7(2):74. PubMed ID: 16369452
[TBL] [Abstract][Full Text] [Related]
19. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
[TBL] [Abstract][Full Text] [Related]
20. [Prevention of target organ damage with modern antihypertensive agents].
Páll D; Katona E; Juhász M; Paragh G
Orv Hetil; 2006 Aug; 147(32):1505-11. PubMed ID: 16981424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
